The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in ...

Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with ...

BCC is new territory for cancer immunotherapies however, and Libtayo is the first drug in the PD-1/PD-L1 inhibitor class to get go-ahead in this common form of skin cancer. It's been cleared for ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

They pointed to "dramatically improved" survival outcomes with immunotherapy, and objective response rates of 44% to 60% with cemiplimab (Libtayo ... ICI therapy for skin cancer, with seven ...

Along with first-line PDL1-positive NSCLC, Libtayo is also used to treat two forms of skin cancer – cutaneous squamous cell carcinoma and basal cell carcinoma. Merck claims adjuvant win in ...

Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Libtayo is targeting new approvals in skin and lung cancers. Dupixent is expanding into COPD, chronic urticaria, and bullous pemphigoid. Baron Health Care Fun invested in Regeneron ...

Having a tattoo has been linked to a higher risk of conditions like lymphoma and skin cancer, but the situation isn't clear-cut ...